cohortId,targetId,targetName,subgroupId,subgroupName,cohortType
1009,1009,Amoxicillin,0,All,Target
1103,1103,antibiotics in SCYLLA,0,All,Target
1010,1010,Ceftriaxone,0,All,Target
1008,1008,Fluoroquinolones,0,All,Target
1007,1007,Azithromycin,0,All,Target
1105,1105,antidiabetics in SCYLLA,0,All,Target
1065,1065,DPP-4 inhibitors,0,All,Target
1067,1067,GLP1 inhibitors,0,All,Target
1064,1064,metformin,0,All,Target
1066,1066,SGLT2 inhibitors,0,All,Target
1052,1052,ACE inhibitors,0,All,Target
1053,1053,Angiotensin receptor blockers (ARBs),0,All,Target
1104,1104,concomitant cardiovascular prevention therapies in SCYLLA,0,All,Target
1077,1077,Losartan,0,All,Target
1054,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),0,All,Target
1055,1055,Thiazide or thiazide-like diuretics,0,All,Target
1041,1041,acenocoumarol,0,All,Target
1047,1047,alteplase,0,All,Target
1102,1102,antithrombotics in SCYLLA,0,All,Target
1042,1042,apixaban,0,All,Target
1045,1045,aspirin,0,All,Target
1043,1043,bemiparin,0,All,Target
1044,1044,clopidogrel,0,All,Target
1039,1039,dabigatran,0,All,Target
1038,1038,edoxaban,0,All,Target
1037,1037,enoxaparin,0,All,Target
1036,1036,heparin,0,All,Target
1046,1046,prasugrel,0,All,Target
1040,1040,rivaroxaban,0,All,Target
1035,1035,warfarin,0,All,Target
1100,1100,antivirals in SCYLLA,0,All,Target
1006,1006,Chloroquine,0,All,Target
1082,1082,emtricitabine,0,All,Target
1029,1029,favipiravir,0,All,Target
1024,1024,HIV Protease inhibitors,0,All,Target
1001,1001,Hydroxychloroquine ,0,All,Target
1004,1004,Hydroxychloroquine + Amoxicillin,0,All,Target
1002,1002,Hydroxychloroquine + Azithromycin ,0,All,Target
1005,1005,Hydroxychloroquine + ceftriaxone,0,All,Target
1003,1003,Hydroxychloroquine + Fluoroquinolones,0,All,Target
1028,1028,Interferon alfa 2a,0,All,Target
1027,1027,Interferon beta 1a,0,All,Target
1026,1026,Interferon beta 1b,0,All,Target
1034,1034,itraconazole,0,All,Target
1033,1033,Ivermectin,0,All,Target
1032,1032,oseltamivir,0,All,Target
1059,1059,raloxifene,0,All,Target
1030,1030,Remdesivir,0,All,Target
1031,1031,ribavirin,0,All,Target
1025,1025,ritonavir/lopinavir,0,All,Target
1080,1080,abiraterone,0,All,Target
1070,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",0,All,Target
1048,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",0,All,Target
1106,1106,concomitant therapies in SCYLLA,0,All,Target
1075,1075,BCG vaccine,0,All,Target
1081,1081,bicalutamide,0,All,Target
1076,1076,Colchicine,0,All,Target
1073,1073,doxazosin,0,All,Target
1071,1071,prazosin,0,All,Target
1074,1074,tamsulosin,0,All,Target
1072,1072,terazosin,0,All,Target
1049,1049,tranexamic acid,0,All,Target
1063,1063,Statins,0,All,Target
1019,1019,adalimumab,0,All,Target
1023,1023,Anakinra,0,All,Target
1101,1101,immune-based therapies in SCYLLA,0,All,Target
1016,1016,baricitinib,0,All,Target
1060,1060,Bevacizumab,0,All,Target
1078,1078,cholecalciferol,0,All,Target
1057,1057,dexamethasone,0,All,Target
1062,1062,eculizumab ,0,All,Target
1020,1020,etanercept,0,All,Target
1069,1069,famotidine,0,All,Target
1061,1061,Fingolimod,0,All,Target
1068,1068,H2 receptor antagonist,0,All,Target
1056,1056,Hydrocortisone,0,All,Target
1079,1079,Ibrutinib,0,All,Target
1011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",0,All,Target
1021,1021,infliximab,0,All,Target
1015,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",0,All,Target
1058,1058,prednisone or prednisolone,0,All,Target
1050,1050,Ruxolitinib,0,All,Target
1014,1014,sarilumab,0,All,Target
1013,1013,siltuximab,0,All,Target
1083,1083,tacrolimus,0,All,Target
1018,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",0,All,Target
1012,1012,tocilizumab,0,All,Target
1017,1017,tofacitinib,0,All,Target
1022,1022,ustekinumab,0,All,Target
1001000011,1001,Hydroxychloroquine ,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1002000011,1002,Hydroxychloroquine + Azithromycin ,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1003000011,1003,Hydroxychloroquine + Fluoroquinolones,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1004000011,1004,Hydroxychloroquine + Amoxicillin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1005000011,1005,Hydroxychloroquine + ceftriaxone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1006000011,1006,Chloroquine,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1007000011,1007,Azithromycin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1008000011,1008,Fluoroquinolones,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1009000011,1009,Amoxicillin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1010000011,1010,Ceftriaxone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1011000011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1012000011,1012,tocilizumab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1013000011,1013,siltuximab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1014000011,1014,sarilumab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1015000011,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1016000011,1016,baricitinib,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1017000011,1017,tofacitinib,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1018000011,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1019000011,1019,adalimumab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1020000011,1020,etanercept,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1021000011,1021,infliximab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1022000011,1022,ustekinumab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1023000011,1023,Anakinra,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1024000011,1024,HIV Protease inhibitors,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1025000011,1025,ritonavir/lopinavir,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1026000011,1026,Interferon beta 1b,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1027000011,1027,Interferon beta 1a,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1028000011,1028,Interferon alfa 2a,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1029000011,1029,favipiravir,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1030000011,1030,Remdesivir,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1031000011,1031,ribavirin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1032000011,1032,oseltamivir,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1033000011,1033,Ivermectin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1034000011,1034,itraconazole,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1035000011,1035,warfarin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1036000011,1036,heparin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1037000011,1037,enoxaparin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1038000011,1038,edoxaban,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1039000011,1039,dabigatran,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1040000011,1040,rivaroxaban,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1041000011,1041,acenocoumarol,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1042000011,1042,apixaban,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1043000011,1043,bemiparin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1044000011,1044,clopidogrel,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1045000011,1045,aspirin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1046000011,1046,prasugrel,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1047000011,1047,alteplase,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1048000011,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1049000011,1049,tranexamic acid,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1050000011,1050,Ruxolitinib,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1052000011,1052,ACE inhibitors,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1053000011,1053,Angiotensin receptor blockers (ARBs),1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1054000011,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1055000011,1055,Thiazide or thiazide-like diuretics,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1056000011,1056,Hydrocortisone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1057000011,1057,dexamethasone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1058000011,1058,prednisone or prednisolone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1059000011,1059,raloxifene,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1060000011,1060,Bevacizumab,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1061000011,1061,Fingolimod,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1062000011,1062,eculizumab ,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1063000011,1063,Statins,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1064000011,1064,metformin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1065000011,1065,DPP-4 inhibitors,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1066000011,1066,SGLT2 inhibitors,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1067000011,1067,GLP1 inhibitors,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1068000011,1068,H2 receptor antagonist,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1069000011,1069,famotidine,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1070000011,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1071000011,1071,prazosin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1072000011,1072,terazosin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1073000011,1073,doxazosin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1074000011,1074,tamsulosin,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1075000011,1075,BCG vaccine,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1076000011,1076,Colchicine,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1077000011,1077,Losartan,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1078000011,1078,cholecalciferol,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1079000011,1079,Ibrutinib,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1080000011,1080,abiraterone,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1081000011,1081,bicalutamide,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1082000011,1082,emtricitabine,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1083000011,1083,tacrolimus,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1100000011,1100,antivirals in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1101000011,1101,immune-based therapies in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1102000011,1102,antithrombotics in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1103000011,1103,antibiotics in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1104000011,1104,concomitant cardiovascular prevention therapies in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1105000011,1105,antidiabetics in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1106000011,1106,concomitant therapies in SCYLLA,1,with Treatment administered on the date of admission of hospitalization and prior to intensive services and 365d prior observation,TwS
1001000021,1001,Hydroxychloroquine ,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1002000021,1002,Hydroxychloroquine + Azithromycin ,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1003000021,1003,Hydroxychloroquine + Fluoroquinolones,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1004000021,1004,Hydroxychloroquine + Amoxicillin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1005000021,1005,Hydroxychloroquine + ceftriaxone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1006000021,1006,Chloroquine,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1007000021,1007,Azithromycin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1008000021,1008,Fluoroquinolones,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1009000021,1009,Amoxicillin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1010000021,1010,Ceftriaxone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1011000021,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1012000021,1012,tocilizumab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1013000021,1013,siltuximab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1014000021,1014,sarilumab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1015000021,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1016000021,1016,baricitinib,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1017000021,1017,tofacitinib,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1018000021,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1019000021,1019,adalimumab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1020000021,1020,etanercept,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1021000021,1021,infliximab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1022000021,1022,ustekinumab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1023000021,1023,Anakinra,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1024000021,1024,HIV Protease inhibitors,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1025000021,1025,ritonavir/lopinavir,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1026000021,1026,Interferon beta 1b,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1027000021,1027,Interferon beta 1a,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1028000021,1028,Interferon alfa 2a,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1029000021,1029,favipiravir,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1030000021,1030,Remdesivir,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1031000021,1031,ribavirin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1032000021,1032,oseltamivir,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1033000021,1033,Ivermectin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1034000021,1034,itraconazole,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1035000021,1035,warfarin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1036000021,1036,heparin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1037000021,1037,enoxaparin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1038000021,1038,edoxaban,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1039000021,1039,dabigatran,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1040000021,1040,rivaroxaban,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1041000021,1041,acenocoumarol,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1042000021,1042,apixaban,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1043000021,1043,bemiparin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1044000021,1044,clopidogrel,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1045000021,1045,aspirin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1046000021,1046,prasugrel,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1047000021,1047,alteplase,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1048000021,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1049000021,1049,tranexamic acid,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1050000021,1050,Ruxolitinib,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1052000021,1052,ACE inhibitors,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1053000021,1053,Angiotensin receptor blockers (ARBs),2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1054000021,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1055000021,1055,Thiazide or thiazide-like diuretics,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1056000021,1056,Hydrocortisone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1057000021,1057,dexamethasone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1058000021,1058,prednisone or prednisolone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1059000021,1059,raloxifene,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1060000021,1060,Bevacizumab,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1061000021,1061,Fingolimod,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1062000021,1062,eculizumab ,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1063000021,1063,Statins,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1064000021,1064,metformin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1065000021,1065,DPP-4 inhibitors,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1066000021,1066,SGLT2 inhibitors,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1067000021,1067,GLP1 inhibitors,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1068000021,1068,H2 receptor antagonist,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1069000021,1069,famotidine,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1070000021,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1071000021,1071,prazosin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1072000021,1072,terazosin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1073000021,1073,doxazosin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1074000021,1074,tamsulosin,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1075000021,1075,BCG vaccine,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1076000021,1076,Colchicine,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1077000021,1077,Losartan,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1078000021,1078,cholecalciferol,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1079000021,1079,Ibrutinib,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1080000021,1080,abiraterone,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1081000021,1081,bicalutamide,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1082000021,1082,emtricitabine,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1083000021,1083,tacrolimus,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1100000021,1100,antivirals in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1101000021,1101,immune-based therapies in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1102000021,1102,antithrombotics in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1103000021,1103,antibiotics in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1104000021,1104,concomitant cardiovascular prevention therapies in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1105000021,1105,antidiabetics in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1106000021,1106,concomitant therapies in SCYLLA,2,"with Treatment administered on the date of
admission of hospitalization and prior to intensive services, with no prior observation",TwS
1001000031,1001,Hydroxychloroquine ,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1002000031,1002,Hydroxychloroquine + Azithromycin ,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1003000031,1003,Hydroxychloroquine + Fluoroquinolones,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1004000031,1004,Hydroxychloroquine + Amoxicillin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1005000031,1005,Hydroxychloroquine + ceftriaxone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1006000031,1006,Chloroquine,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1007000031,1007,Azithromycin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1008000031,1008,Fluoroquinolones,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1009000031,1009,Amoxicillin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1010000031,1010,Ceftriaxone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1011000031,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1012000031,1012,tocilizumab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1013000031,1013,siltuximab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1014000031,1014,sarilumab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1015000031,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1016000031,1016,baricitinib,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1017000031,1017,tofacitinib,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1018000031,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1019000031,1019,adalimumab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1020000031,1020,etanercept,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1021000031,1021,infliximab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1022000031,1022,ustekinumab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1023000031,1023,Anakinra,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1024000031,1024,HIV Protease inhibitors,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1025000031,1025,ritonavir/lopinavir,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1026000031,1026,Interferon beta 1b,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1027000031,1027,Interferon beta 1a,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1028000031,1028,Interferon alfa 2a,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1029000031,1029,favipiravir,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1030000031,1030,Remdesivir,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1031000031,1031,ribavirin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1032000031,1032,oseltamivir,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1033000031,1033,Ivermectin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1034000031,1034,itraconazole,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1035000031,1035,warfarin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1036000031,1036,heparin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1037000031,1037,enoxaparin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1038000031,1038,edoxaban,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1039000031,1039,dabigatran,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1040000031,1040,rivaroxaban,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1041000031,1041,acenocoumarol,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1042000031,1042,apixaban,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1043000031,1043,bemiparin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1044000031,1044,clopidogrel,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1045000031,1045,aspirin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1046000031,1046,prasugrel,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1047000031,1047,alteplase,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1048000031,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1049000031,1049,tranexamic acid,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1050000031,1050,Ruxolitinib,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1052000031,1052,ACE inhibitors,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1053000031,1053,Angiotensin receptor blockers (ARBs),3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1054000031,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1055000031,1055,Thiazide or thiazide-like diuretics,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1056000031,1056,Hydrocortisone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1057000031,1057,dexamethasone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1058000031,1058,prednisone or prednisolone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1059000031,1059,raloxifene,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1060000031,1060,Bevacizumab,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1061000031,1061,Fingolimod,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1062000031,1062,eculizumab ,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1063000031,1063,Statins,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1064000031,1064,metformin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1065000031,1065,DPP-4 inhibitors,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1066000031,1066,SGLT2 inhibitors,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1067000031,1067,GLP1 inhibitors,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1068000031,1068,H2 receptor antagonist,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1069000031,1069,famotidine,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1070000031,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1071000031,1071,prazosin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1072000031,1072,terazosin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1073000031,1073,doxazosin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1074000031,1074,tamsulosin,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1075000031,1075,BCG vaccine,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1076000031,1076,Colchicine,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1077000031,1077,Losartan,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1078000031,1078,cholecalciferol,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1079000031,1079,Ibrutinib,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1080000031,1080,abiraterone,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1081000031,1081,bicalutamide,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1082000031,1082,emtricitabine,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1083000031,1083,tacrolimus,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1100000031,1100,antivirals in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1101000031,1101,immune-based therapies in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1102000031,1102,antithrombotics in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1103000031,1103,antibiotics in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1104000031,1104,concomitant cardiovascular prevention therapies in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1105000031,1105,antidiabetics in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1106000031,1106,concomitant therapies in SCYLLA,3,with Treatment administered during hospitalization and prior to intensive services and 365d prior observation,TwS
1001020011,1001,Hydroxychloroquine ,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1002020011,1002,Hydroxychloroquine + Azithromycin ,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1003020011,1003,Hydroxychloroquine + Fluoroquinolones,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1004020011,1004,Hydroxychloroquine + Amoxicillin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1005020011,1005,Hydroxychloroquine + ceftriaxone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1006020011,1006,Chloroquine,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1007020011,1007,Azithromycin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1008020011,1008,Fluoroquinolones,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1009020011,1009,Amoxicillin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1010020011,1010,Ceftriaxone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1011020011,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1012020011,1012,tocilizumab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1013020011,1013,siltuximab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1014020011,1014,sarilumab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1015020011,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1016020011,1016,baricitinib,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1017020011,1017,tofacitinib,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1018020011,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1019020011,1019,adalimumab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1020020011,1020,etanercept,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1021020011,1021,infliximab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1022020011,1022,ustekinumab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1023020011,1023,Anakinra,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1024020011,1024,HIV Protease inhibitors,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1025020011,1025,ritonavir/lopinavir,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1026020011,1026,Interferon beta 1b,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1027020011,1027,Interferon beta 1a,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1028020011,1028,Interferon alfa 2a,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1029020011,1029,favipiravir,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1030020011,1030,Remdesivir,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1031020011,1031,ribavirin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1032020011,1032,oseltamivir,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1033020011,1033,Ivermectin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1034020011,1034,itraconazole,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1035020011,1035,warfarin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1036020011,1036,heparin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1037020011,1037,enoxaparin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1038020011,1038,edoxaban,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1039020011,1039,dabigatran,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1040020011,1040,rivaroxaban,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1041020011,1041,acenocoumarol,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1042020011,1042,apixaban,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1043020011,1043,bemiparin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1044020011,1044,clopidogrel,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1045020011,1045,aspirin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1046020011,1046,prasugrel,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1047020011,1047,alteplase,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1048020011,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1049020011,1049,tranexamic acid,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1050020011,1050,Ruxolitinib,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1052020011,1052,ACE inhibitors,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1053020011,1053,Angiotensin receptor blockers (ARBs),2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1054020011,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1055020011,1055,Thiazide or thiazide-like diuretics,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1056020011,1056,Hydrocortisone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1057020011,1057,dexamethasone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1058020011,1058,prednisone or prednisolone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1059020011,1059,raloxifene,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1060020011,1060,Bevacizumab,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1061020011,1061,Fingolimod,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1062020011,1062,eculizumab ,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1063020011,1063,Statins,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1064020011,1064,metformin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1065020011,1065,DPP-4 inhibitors,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1066020011,1066,SGLT2 inhibitors,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1067020011,1067,GLP1 inhibitors,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1068020011,1068,H2 receptor antagonist,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1069020011,1069,famotidine,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1070020011,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1071020011,1071,prazosin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1072020011,1072,terazosin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1073020011,1073,doxazosin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1074020011,1074,tamsulosin,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1075020011,1075,BCG vaccine,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1076020011,1076,Colchicine,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1077020011,1077,Losartan,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1078020011,1078,cholecalciferol,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1079020011,1079,Ibrutinib,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1080020011,1080,abiraterone,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1081020011,1081,bicalutamide,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1082020011,1082,emtricitabine,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1083020011,1083,tacrolimus,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1100020011,1100,antivirals in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1101020011,1101,immune-based therapies in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1102020011,1102,antithrombotics in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1103020011,1103,antibiotics in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1104020011,1104,concomitant cardiovascular prevention therapies in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1105020011,1105,antidiabetics in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1106020011,1106,concomitant therapies in SCYLLA,2001,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services,TwS
1001020021,1001,Hydroxychloroquine ,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1002020021,1002,Hydroxychloroquine + Azithromycin ,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1003020021,1003,Hydroxychloroquine + Fluoroquinolones,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1004020021,1004,Hydroxychloroquine + Amoxicillin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1005020021,1005,Hydroxychloroquine + ceftriaxone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1006020021,1006,Chloroquine,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1007020021,1007,Azithromycin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1008020021,1008,Fluoroquinolones,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1009020021,1009,Amoxicillin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1010020021,1010,Ceftriaxone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1011020021,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1012020021,1012,tocilizumab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1013020021,1013,siltuximab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1014020021,1014,sarilumab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1015020021,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1016020021,1016,baricitinib,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1017020021,1017,tofacitinib,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1018020021,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1019020021,1019,adalimumab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1020020021,1020,etanercept,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1021020021,1021,infliximab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1022020021,1022,ustekinumab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1023020021,1023,Anakinra,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1024020021,1024,HIV Protease inhibitors,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1025020021,1025,ritonavir/lopinavir,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1026020021,1026,Interferon beta 1b,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1027020021,1027,Interferon beta 1a,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1028020021,1028,Interferon alfa 2a,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1029020021,1029,favipiravir,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1030020021,1030,Remdesivir,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1031020021,1031,ribavirin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1032020021,1032,oseltamivir,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1033020021,1033,Ivermectin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1034020021,1034,itraconazole,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1035020021,1035,warfarin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1036020021,1036,heparin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1037020021,1037,enoxaparin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1038020021,1038,edoxaban,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1039020021,1039,dabigatran,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1040020021,1040,rivaroxaban,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1041020021,1041,acenocoumarol,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1042020021,1042,apixaban,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1043020021,1043,bemiparin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1044020021,1044,clopidogrel,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1045020021,1045,aspirin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1046020021,1046,prasugrel,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1047020021,1047,alteplase,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1048020021,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1049020021,1049,tranexamic acid,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1050020021,1050,Ruxolitinib,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1052020021,1052,ACE inhibitors,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1053020021,1053,Angiotensin receptor blockers (ARBs),2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1054020021,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1055020021,1055,Thiazide or thiazide-like diuretics,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1056020021,1056,Hydrocortisone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1057020021,1057,dexamethasone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1058020021,1058,prednisone or prednisolone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1059020021,1059,raloxifene,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1060020021,1060,Bevacizumab,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1061020021,1061,Fingolimod,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1062020021,1062,eculizumab ,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1063020021,1063,Statins,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1064020021,1064,metformin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1065020021,1065,DPP-4 inhibitors,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1066020021,1066,SGLT2 inhibitors,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1067020021,1067,GLP1 inhibitors,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1068020021,1068,H2 receptor antagonist,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1069020021,1069,famotidine,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1070020021,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1071020021,1071,prazosin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1072020021,1072,terazosin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1073020021,1073,doxazosin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1074020021,1074,tamsulosin,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1075020021,1075,BCG vaccine,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1076020021,1076,Colchicine,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1077020021,1077,Losartan,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1078020021,1078,cholecalciferol,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1079020021,1079,Ibrutinib,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1080020021,1080,abiraterone,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1081020021,1081,bicalutamide,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1082020021,1082,emtricitabine,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1083020021,1083,tacrolimus,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1100020021,1100,antivirals in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1101020021,1101,immune-based therapies in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1102020021,1102,antithrombotics in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1103020021,1103,antibiotics in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1104020021,1104,concomitant cardiovascular prevention therapies in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1105020021,1105,antidiabetics in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1106020021,1106,concomitant therapies in SCYLLA,2002,with Persons with a COVID-19 diagnosis record or a SARS-CoV-2 positive test prior to inpatient visit or intensive services and 365d prior observation,TwS
1001020031,1001,Hydroxychloroquine ,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1002020031,1002,Hydroxychloroquine + Azithromycin ,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1003020031,1003,Hydroxychloroquine + Fluoroquinolones,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1004020031,1004,Hydroxychloroquine + Amoxicillin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1005020031,1005,Hydroxychloroquine + ceftriaxone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1006020031,1006,Chloroquine,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1007020031,1007,Azithromycin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1008020031,1008,Fluoroquinolones,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1009020031,1009,Amoxicillin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1010020031,1010,Ceftriaxone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1011020031,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1012020031,1012,tocilizumab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1013020031,1013,siltuximab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1014020031,1014,sarilumab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1015020031,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1016020031,1016,baricitinib,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1017020031,1017,tofacitinib,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1018020031,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1019020031,1019,adalimumab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1020020031,1020,etanercept,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1021020031,1021,infliximab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1022020031,1022,ustekinumab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1023020031,1023,Anakinra,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1024020031,1024,HIV Protease inhibitors,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1025020031,1025,ritonavir/lopinavir,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1026020031,1026,Interferon beta 1b,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1027020031,1027,Interferon beta 1a,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1028020031,1028,Interferon alfa 2a,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1029020031,1029,favipiravir,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1030020031,1030,Remdesivir,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1031020031,1031,ribavirin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1032020031,1032,oseltamivir,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1033020031,1033,Ivermectin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1034020031,1034,itraconazole,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1035020031,1035,warfarin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1036020031,1036,heparin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1037020031,1037,enoxaparin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1038020031,1038,edoxaban,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1039020031,1039,dabigatran,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1040020031,1040,rivaroxaban,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1041020031,1041,acenocoumarol,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1042020031,1042,apixaban,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1043020031,1043,bemiparin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1044020031,1044,clopidogrel,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1045020031,1045,aspirin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1046020031,1046,prasugrel,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1047020031,1047,alteplase,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1048020031,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1049020031,1049,tranexamic acid,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1050020031,1050,Ruxolitinib,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1052020031,1052,ACE inhibitors,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1053020031,1053,Angiotensin receptor blockers (ARBs),2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1054020031,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1055020031,1055,Thiazide or thiazide-like diuretics,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1056020031,1056,Hydrocortisone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1057020031,1057,dexamethasone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1058020031,1058,prednisone or prednisolone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1059020031,1059,raloxifene,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1060020031,1060,Bevacizumab,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1061020031,1061,Fingolimod,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1062020031,1062,eculizumab ,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1063020031,1063,Statins,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1064020031,1064,metformin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1065020031,1065,DPP-4 inhibitors,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1066020031,1066,SGLT2 inhibitors,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1067020031,1067,GLP1 inhibitors,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1068020031,1068,H2 receptor antagonist,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1069020031,1069,famotidine,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1070020031,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1071020031,1071,prazosin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1072020031,1072,terazosin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1073020031,1073,doxazosin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1074020031,1074,tamsulosin,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1075020031,1075,BCG vaccine,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1076020031,1076,Colchicine,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1077020031,1077,Losartan,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1078020031,1078,cholecalciferol,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1079020031,1079,Ibrutinib,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1080020031,1080,abiraterone,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1081020031,1081,bicalutamide,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1082020031,1082,emtricitabine,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1083020031,1083,tacrolimus,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1100020031,1100,antivirals in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1101020031,1101,immune-based therapies in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1102020031,1102,antithrombotics in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1103020031,1103,antibiotics in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1104020031,1104,concomitant cardiovascular prevention therapies in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1105020031,1105,antidiabetics in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1106020031,1106,concomitant therapies in SCYLLA,2003,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services",TwS
1001020041,1001,Hydroxychloroquine ,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1002020041,1002,Hydroxychloroquine + Azithromycin ,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1003020041,1003,Hydroxychloroquine + Fluoroquinolones,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1004020041,1004,Hydroxychloroquine + Amoxicillin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1005020041,1005,Hydroxychloroquine + ceftriaxone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1006020041,1006,Chloroquine,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1007020041,1007,Azithromycin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1008020041,1008,Fluoroquinolones,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1009020041,1009,Amoxicillin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1010020041,1010,Ceftriaxone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1011020041,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1012020041,1012,tocilizumab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1013020041,1013,siltuximab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1014020041,1014,sarilumab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1015020041,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1016020041,1016,baricitinib,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1017020041,1017,tofacitinib,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1018020041,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1019020041,1019,adalimumab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1020020041,1020,etanercept,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1021020041,1021,infliximab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1022020041,1022,ustekinumab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1023020041,1023,Anakinra,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1024020041,1024,HIV Protease inhibitors,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1025020041,1025,ritonavir/lopinavir,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1026020041,1026,Interferon beta 1b,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1027020041,1027,Interferon beta 1a,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1028020041,1028,Interferon alfa 2a,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1029020041,1029,favipiravir,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1030020041,1030,Remdesivir,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1031020041,1031,ribavirin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1032020041,1032,oseltamivir,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1033020041,1033,Ivermectin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1034020041,1034,itraconazole,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1035020041,1035,warfarin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1036020041,1036,heparin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1037020041,1037,enoxaparin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1038020041,1038,edoxaban,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1039020041,1039,dabigatran,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1040020041,1040,rivaroxaban,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1041020041,1041,acenocoumarol,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1042020041,1042,apixaban,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1043020041,1043,bemiparin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1044020041,1044,clopidogrel,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1045020041,1045,aspirin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1046020041,1046,prasugrel,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1047020041,1047,alteplase,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1048020041,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1049020041,1049,tranexamic acid,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1050020041,1050,Ruxolitinib,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1052020041,1052,ACE inhibitors,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1053020041,1053,Angiotensin receptor blockers (ARBs),2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1054020041,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1055020041,1055,Thiazide or thiazide-like diuretics,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1056020041,1056,Hydrocortisone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1057020041,1057,dexamethasone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1058020041,1058,prednisone or prednisolone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1059020041,1059,raloxifene,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1060020041,1060,Bevacizumab,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1061020041,1061,Fingolimod,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1062020041,1062,eculizumab ,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1063020041,1063,Statins,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1064020041,1064,metformin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1065020041,1065,DPP-4 inhibitors,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1066020041,1066,SGLT2 inhibitors,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1067020041,1067,GLP1 inhibitors,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1068020041,1068,H2 receptor antagonist,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1069020041,1069,famotidine,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1070020041,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1071020041,1071,prazosin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1072020041,1072,terazosin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1073020041,1073,doxazosin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1074020041,1074,tamsulosin,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1075020041,1075,BCG vaccine,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1076020041,1076,Colchicine,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1077020041,1077,Losartan,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1078020041,1078,cholecalciferol,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1079020041,1079,Ibrutinib,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1080020041,1080,abiraterone,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1081020041,1081,bicalutamide,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1082020041,1082,emtricitabine,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1083020041,1083,tacrolimus,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1100020041,1100,antivirals in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1101020041,1101,immune-based therapies in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1102020041,1102,antithrombotics in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1103020041,1103,antibiotics in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1104020041,1104,concomitant cardiovascular prevention therapies in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1105020041,1105,antidiabetics in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1106020041,1106,concomitant therapies in SCYLLA,2004,"with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test, inpatient setting without or prior to intensive services and 365d prior observation",TwS
1001020051,1001,Hydroxychloroquine ,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1002020051,1002,Hydroxychloroquine + Azithromycin ,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1003020051,1003,Hydroxychloroquine + Fluoroquinolones,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1004020051,1004,Hydroxychloroquine + Amoxicillin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1005020051,1005,Hydroxychloroquine + ceftriaxone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1006020051,1006,Chloroquine,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1007020051,1007,Azithromycin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1008020051,1008,Fluoroquinolones,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1009020051,1009,Amoxicillin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1010020051,1010,Ceftriaxone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1011020051,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1012020051,1012,tocilizumab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1013020051,1013,siltuximab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1014020051,1014,sarilumab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1015020051,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1016020051,1016,baricitinib,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1017020051,1017,tofacitinib,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1018020051,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1019020051,1019,adalimumab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1020020051,1020,etanercept,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1021020051,1021,infliximab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1022020051,1022,ustekinumab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1023020051,1023,Anakinra,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1024020051,1024,HIV Protease inhibitors,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1025020051,1025,ritonavir/lopinavir,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1026020051,1026,Interferon beta 1b,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1027020051,1027,Interferon beta 1a,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1028020051,1028,Interferon alfa 2a,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1029020051,1029,favipiravir,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1030020051,1030,Remdesivir,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1031020051,1031,ribavirin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1032020051,1032,oseltamivir,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1033020051,1033,Ivermectin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1034020051,1034,itraconazole,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1035020051,1035,warfarin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1036020051,1036,heparin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1037020051,1037,enoxaparin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1038020051,1038,edoxaban,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1039020051,1039,dabigatran,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1040020051,1040,rivaroxaban,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1041020051,1041,acenocoumarol,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1042020051,1042,apixaban,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1043020051,1043,bemiparin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1044020051,1044,clopidogrel,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1045020051,1045,aspirin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1046020051,1046,prasugrel,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1047020051,1047,alteplase,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1048020051,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1049020051,1049,tranexamic acid,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1050020051,1050,Ruxolitinib,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1052020051,1052,ACE inhibitors,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1053020051,1053,Angiotensin receptor blockers (ARBs),2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1054020051,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1055020051,1055,Thiazide or thiazide-like diuretics,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1056020051,1056,Hydrocortisone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1057020051,1057,dexamethasone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1058020051,1058,prednisone or prednisolone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1059020051,1059,raloxifene,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1060020051,1060,Bevacizumab,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1061020051,1061,Fingolimod,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1062020051,1062,eculizumab ,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1063020051,1063,Statins,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1064020051,1064,metformin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1065020051,1065,DPP-4 inhibitors,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1066020051,1066,SGLT2 inhibitors,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1067020051,1067,GLP1 inhibitors,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1068020051,1068,H2 receptor antagonist,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1069020051,1069,famotidine,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1070020051,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1071020051,1071,prazosin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1072020051,1072,terazosin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1073020051,1073,doxazosin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1074020051,1074,tamsulosin,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1075020051,1075,BCG vaccine,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1076020051,1076,Colchicine,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1077020051,1077,Losartan,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1078020051,1078,cholecalciferol,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1079020051,1079,Ibrutinib,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1080020051,1080,abiraterone,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1081020051,1081,bicalutamide,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1082020051,1082,emtricitabine,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1083020051,1083,tacrolimus,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1100020051,1100,antivirals in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1101020051,1101,immune-based therapies in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1102020051,1102,antithrombotics in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1103020051,1103,antibiotics in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1104020051,1104,concomitant cardiovascular prevention therapies in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1105020051,1105,antidiabetics in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1106020051,1106,concomitant therapies in SCYLLA,2005,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services,TwS
1001020061,1001,Hydroxychloroquine ,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1002020061,1002,Hydroxychloroquine + Azithromycin ,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1003020061,1003,Hydroxychloroquine + Fluoroquinolones,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1004020061,1004,Hydroxychloroquine + Amoxicillin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1005020061,1005,Hydroxychloroquine + ceftriaxone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1006020061,1006,Chloroquine,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1007020061,1007,Azithromycin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1008020061,1008,Fluoroquinolones,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1009020061,1009,Amoxicillin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1010020061,1010,Ceftriaxone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1011020061,1011,"IL6 inhibitors (tocilizumab, sarilumab, siltuximab)",2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1012020061,1012,tocilizumab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1013020061,1013,siltuximab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1014020061,1014,sarilumab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1015020061,1015,"JAK inhibitors (ruxolitinib, tofacitinib, oclacitinib, baricitinib, fedratinib, upadacitinib)",2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1016020061,1016,baricitinib,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1017020061,1017,tofacitinib,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1018020061,1018,"TNF inhibitors (infliximab, golimumab, etanercept, certolizumab pegol, adalimumab)",2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1019020061,1019,adalimumab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1020020061,1020,etanercept,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1021020061,1021,infliximab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1022020061,1022,ustekinumab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1023020061,1023,Anakinra,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1024020061,1024,HIV Protease inhibitors,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1025020061,1025,ritonavir/lopinavir,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1026020061,1026,Interferon beta 1b,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1027020061,1027,Interferon beta 1a,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1028020061,1028,Interferon alfa 2a,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1029020061,1029,favipiravir,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1030020061,1030,Remdesivir,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1031020061,1031,ribavirin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1032020061,1032,oseltamivir,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1033020061,1033,Ivermectin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1034020061,1034,itraconazole,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1035020061,1035,warfarin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1036020061,1036,heparin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1037020061,1037,enoxaparin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1038020061,1038,edoxaban,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1039020061,1039,dabigatran,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1040020061,1040,rivaroxaban,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1041020061,1041,acenocoumarol,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1042020061,1042,apixaban,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1043020061,1043,bemiparin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1044020061,1044,clopidogrel,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1045020061,1045,aspirin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1046020061,1046,prasugrel,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1047020061,1047,alteplase,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1048020061,1048,"Antifibrinolytics (tranexamic acid, aminocaproic acid)",2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1049020061,1049,tranexamic acid,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1050020061,1050,Ruxolitinib,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1052020061,1052,ACE inhibitors,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1053020061,1053,Angiotensin receptor blockers (ARBs),2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1054020061,1054,Non-Dihydropyridine Calcium Channel Blocker (ndCCB),2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1055020061,1055,Thiazide or thiazide-like diuretics,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1056020061,1056,Hydrocortisone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1057020061,1057,dexamethasone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1058020061,1058,prednisone or prednisolone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1059020061,1059,raloxifene,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1060020061,1060,Bevacizumab,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1061020061,1061,Fingolimod,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1062020061,1062,eculizumab ,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1063020061,1063,Statins,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1064020061,1064,metformin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1065020061,1065,DPP-4 inhibitors,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1066020061,1066,SGLT2 inhibitors,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1067020061,1067,GLP1 inhibitors,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1068020061,1068,H2 receptor antagonist,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1069020061,1069,famotidine,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1070020061,1070,"Alpha-1 blockers (Doxazosin, prazosin, terazosin, tasulosin, silodosin, alfuzosin)",2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1071020061,1071,prazosin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1072020061,1072,terazosin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1073020061,1073,doxazosin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1074020061,1074,tamsulosin,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1075020061,1075,BCG vaccine,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1076020061,1076,Colchicine,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1077020061,1077,Losartan,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1078020061,1078,cholecalciferol,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1079020061,1079,Ibrutinib,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1080020061,1080,abiraterone,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1081020061,1081,bicalutamide,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1082020061,1082,emtricitabine,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1083020061,1083,tacrolimus,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1100020061,1100,antivirals in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1101020061,1101,immune-based therapies in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1102020061,1102,antithrombotics in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1103020061,1103,antibiotics in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1104020061,1104,concomitant cardiovascular prevention therapies in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1105020061,1105,antidiabetics in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
1106020061,1106,concomitant therapies in SCYLLA,2006,with Persons hospitalized with a COVID-19 diagnosis record or a SARS-CoV-2 positive test after intensive services with 365d prior observation,TwS
